Therefore, we aimed to systematically review the efficacy and safety of SGLT2 inhibitors in transplant recipients with diabetes, incorporate recent literature, and quantitatively analyze their efficacy and safety based on comparative studies. The gene discussed is SLC5A2; the disease is diabetes mellitus.